Friday, August 23, 2024 NIAID Vaccine Review Prepares for Future CoV Pandemics Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Credit: NIAID. Acknowledging the potential for a new coronavirus (CoV) to emerge, infect humans, and possibly cause disease, a NIAID research group has shared preparedness recommendations after evaluating more than 10 existing CoV vaccines and another 20 in development. Their advice, published in npj Viruses, emphasizes using a tiered approach and developing vaccines delivered via muscle injection and nasal administration. The tiered approach prioritizes, in descending order: first, creating COVID-19 vaccines that protect against all variants of concern; second, developing an effective vaccine against all sarbecoviruses (e.g. SARS-CoV-1 and SARS-CoV-2); third, making a vaccine against all beta coronaviruses; and lastly, developing a universal coronavirus vaccine. However, the work will be challenging, due to the numerous obstacles CoVs pose as they evolve and diversify.   National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period.  This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107